MINISTRY OF HEALTH AND WELFARE Notice is hereby given, to commence a period of public comments for the draft amendment of "List of Orphan Drug Designations and Approvals"
(一)新增適用罕見疾病防治及藥物法之藥物品項「Ravulizumab」(concentrate for solution for infusion)之認定劑量「100 mg/ml」,及修正適應症為「治療陣發性夜間血紅素尿症(paroxysmal nocturnal hemoglobinuria, PNH)成人病人、治療非典型性尿毒溶血症候群(atypical hemolytic uremic syndrome, aHUS)年齡一個月以上的兒童及成人病人」。
(二)新增認定「Voretigene neparvovec」(concentrate for solution for injection,5x1012 vg/ml)為「適用罕見疾病防治及藥物法之藥物品項」,適應症為「適用於四歲以上因雙對偶基因RPE65突變之萊伯氏先天性黑矇症(Leber congenital amaurosis, LCA),而喪失視力,並具有足夠的存活視網膜細胞的病人」。
(三)新增認定「Satralizumab」(solution for injection,120 mg/ml)為「適用罕見疾病防治及藥物法之藥物品項」,適應症為「適用於治療抗水通道蛋白4抗體陽性[anti-aquaporin-4(AQP4)antibody positive]的泛視神經脊髓炎(neuromyelitis optica spectrum disorder, NMOSD)之成人及12歲以上青少年病人」。
MINISTRY OF HEALTH AND WELFARE Notice is hereby given, for the amendment of "List of Orphan Drug Designations and Approvals" (amendment becomes effective from 31st, January 2023)